Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy"

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer shared his thoughts on. The first caller of the episode inquired about the stock, and Cramer replied:

I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up… I was in San Francisco, and I said, you know what? I get that stock a little down more… But I love Eli Lilly and David Ricks, and what can I say? You know, as long as Eli Lilly and David Ricks are putting up those numbers and they get that pill form soon, I think that Novo is a hold, not a buy.

Novo Nordisk A/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. During the January 10 episode, a caller asked if the stock was a buy, sell, or hold. Cramer responded similarly as he said:

No, I would hold it. I met with the CEO last week. I kind of, I liked him a lot. Now, I met with Dave Ricks from Lilly, and you know, he’s my favorite, but I’m not going to go against owning some Novo. I think they’re making a turn here. I think that head start they have in the pill is very good.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.